

BLISS GVS PHARMA LIMITED
 Regd Office: 102, Hyde Park, Sakinagar Road,
 Andheri (East), Mumbai - 400 072
 UNAUDITED FINANCIAL RESULTS
 FOR THE QUARTER ENDED 31.12.2014.

SR. NO.	PARTICULARS	STANDALONE					YEAR ENDED 31.03.2014 (AUDITED)
		QUARTER ENDED		9 MONTHS			
		31.12.2014 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.12.2014 (UNAUDITED)	31.12.2013 (UNAUDITED)	
1	INCOME FROM OPERATIONS (a) NET SALES (NET OF EXCISE DUTY) (b) OTHER OPERATING INCOME	8413.00 168.29	8755.60 173.72	5683.77 114.90	24140.57 448.12	22976.12 520.59	28949.25 696.43
	TOTAL INCOME FROM OPERATIONS (NET)	8581.29	8929.41	6000.75	24587.69	23496.71	29045.68
2	EXPENSES a) CONSUMPTION OF RAW MATERIALS b) PURCHASE OF TRADED GOODS c) CHANGES IN INVENTORIES OF FINISHED GOODS, WORK IN PROGRESS, STOCK IN TRADE d) EMPLOYEE BENEFIT EXPENSES e) DEPRECIATION/ AMORTISATION f) OTHER EXPENDITURE TOTAL EXPENSES	4041.61 0.00 -150.36 454.39 131.34 1791.28 6268.06	4190.15 90.32 17.62 468.13 118.48 1327.98 6153.69	2,221.23 0.00 165.13 323.84 128.04 1356.59 4183.93	10,838.66 90.32 135.17 1257.70 362.75 4792.02 17476.62	10,615.19 520.90 428.96 1282.81 446.16 4883.16 17755.92	13517.82 1030.40 60.57 1282.81 446.16 6314.46 22662.42
3	PROFIT FROM OPERATIONS BEFORE OTHER INCOME & FINANCE COST & EXCEPTIONAL ITEMS (1-2)	2313.23	2776.72	1806.82	7121.07	5740.79	6383.66
4	OTHER INCOME	798.28	713.38	145.46	1761.52	2699.80	2789.81
5	PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST (3+4)	3111.49	3489.10	1952.28	8882.59	8440.59	9173.47
6	FINANCE COST	349.61	251.17	220.86	824.76	634.19	943.63
7	PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)	2761.88	3237.93	1731.42	8057.83	7806.40	8229.84
8	EXCEPTIONAL ITEMS						
9	PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)	2761.88	3237.93	1731.42	8057.83	7806.40	8229.84
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	962.62	1081.20	866.59	2702.39	2565.19	2837.19
11	NET PROFIT AFTER TAX FOR THE PERIOD (9-10)	1799.26	2156.73	864.83	5355.44	5241.21	5392.65
14	PAID - UP EQUITY CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)						
16	BASIC AND DILUTED EPS (NOT ANNUALISED)	1.74	2.09	1.00	5.16	5.08	5.22

888

PART - II	PARTICULARS	STANDALONE				YEAR ENDED 31.03.2014 (AUDITED)
		QUARTER ENDED		9 MONTHS		
		31.12.2014 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.12.2013 (UNAUDITED)	31.12.2014 (UNAUDITED)	
A	PARTICULARS OF SHAREHOLDING					
1	AGGREGATE OF NON-PROMOTER SHAREHOLDING - NO. OF SHARES (FACE VALUE RS.1/- EACH) - PERCENTAGE OF SHAREHOLDING (%)	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05	36156842 35.05
2	PROMOTER AND PROMOTER GROUP SHAREHOLDING					
	A) PLEDGE/ENCUMBERED - NO. OF SHARES /FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)					
	B) NOM - ENCUMBERED - NO. OF SHARES /FACE VALUE RE.1/- EACH) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE HOLDING OF PROMOTER & PROMOTER GROUP) - PERCENTAGE OF SHARES (AS % OF THE TOTAL SHARE CAPITAL OF THE COMPANY)	66989630 100.00 64.95	66989630 100.00 64.95	66989630 100.00 64.95	66989630 100.00 64.95	66989630 100.00 64.95

Particulars	Quarter ended 31st December 2014
B	
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	2
Received during the quarter	2
Disposed off during the quarter	-
REMAINING UNSOLVED AT THE END OF THE QUARTER	

NOTES:-

1. THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.
2. DURING THE QUARTER THE COMPANY HAS FORMED A SUBSIDIARY IN UNITED KINGDOM WITH 100% STAKE IN THE NAME OF ASTERISK LIFESCIENCES LTD
3. THE ABOVE RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON 12TH FEBRUARY, 2015
4. THE STATUTORY AUDITORS HAVE CARRIED OUT A LIMITED REVIEW OF THE RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2014
5. FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.
6. DEPRECIATION FOR THE QUARTER IS BASED ON THE SCHEDULE II OF THE COMPANIES ACT 2013 WHICH IS EFFECTIVE FROM APRIL 1, 2014. THIS HAS RESULTED IN A NET ADDITIONAL DEPRECIATION OF RS 28.28 LACS BEING CHARGED TO THE STATEMENT OF PROFIT & LOSS DURING THE QUARTER. FURTHER ASSETS WHOSE USEFUL HAS EXPIRED AS ON APRIL 1, 2014. THE ENTIRE CARRYING VALUE OF THAT DATE HAS BEEN RECOGNISED IN THE OPENING BALANCE OF RETAINED EARNINGS AS SPECIFIED IN THE SCHEDULE II OF THE COMPANIES ACT, 2013.
7. THE BOARD HAS RECOMMENDED AN INTERIM DIVIDEND OF 20% I.E. RS. 2/- PER EQUITY SHARE FOR THE YEAR 2014-2015.

PLACE : MUMBAI
DATE : 12th FEBRUARY 2015

SK

S. N. Kamath
FOR BLISS GYS PHARMA LTD

SD/-
S.N. KAMATH
MANAGING DIRECTOR

B. K. KHARE & Co.

CHARTERED ACCOUNTANTS

T + 91 022 22000607/7318/6360
 + 91 022 66315835/36
 F + 91 022 2200 3476
 E info@bkkhareco.com
 706/708, Sharda Chambers New Marine
 Lines, Mumbai - 400 020, India

Limited Review Report

The Board of Directors
 Bliss GVS Pharma Limited
 Mumbai

We have reviewed the accompanying Statement of unaudited financial results of Bliss GVS Pharma Limited for the period ended December 31, 2014 ("the Statement") except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures, made by the management and have not been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the Accounting Standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B. K. Khare & Co.
 Chartered Accountants
 Firm Registration No. 105102W



Himanshu Chapsey
 Partner
 Membership No. 105731

Place: Mumbai
 Date: February 12, 2015

Pune

T + 91 020 60601005/6/7/8/9
 + 91 020 25666932/32926341
 E bkkpune@bkkhareco.com
 Hotel Swaroop, 4th Floor,
 Lane No.10, Prabhat Road,
 Erandwane, Pune - 411 004, India

Bengaluru

T + 91 80 41105357
 E bkkbengaluru@bkkhareco.com
 101, Money Chambers,
 1st Floor, # 6 K. H. Road,
 Shanthinagar,
 Bengaluru - 560027, India

New Delhi

T + 91 011 4182 8360
 E bkkdelhi@bkkhareco.com
 107, Siddharth Chambers,
 Near IIT Gate,
 Kalu Sarai, Hauz Khas,
 New Delhi - 110 016, India